Advertisement

Drugs & Aging

, Volume 20, Issue 4, pp 241–251 | Cite as

The Perindopril Protection Against Recurrent Stroke Study (PROGRESS)

Clinical Implications for Older Patients with Cerebrovascular Disease
  • Yogini Ratnasabapathy
  • Carlene M. M. Lawes
  • Craig S. AndersonEmail author
Leading Article

Abstract

Blood pressure levels are strongly predictive of the risks of first-ever and recurrent stroke. The benefits of blood pressure-lowering therapy for the prevention of fatal and non-fatal stroke in middle-aged individuals are well established. However, until recently, there has been uncertainty about the consistency of such benefits across different patient groups and in particular, for older people and in those with a history of stroke. This paper discusses the evidence surrounding the effectiveness of blood pressure-lowering therapy, specifically in older patients with a history of stroke, with particular attention paid to the results from the Perindopril Protection Against Recurrent Stroke Study (PROGRESS).

PROGRESS was a randomised, double-blind, placebo-controlled trial of 6105 individuals with a history of cerebrovascular disease recruited from 172 hospital outpatient clinics in ten countries. Participants (mean age 64 years; range 26–91 years) were randomly assigned to receive active treatment with an ACE inhibitor-based blood pressure-lowering regimen (perindopril) with or without addition of the diuretic indapamide, or matched placebo. At the end of follow up (mean of 4 years), active treatment reduced the incidence of total stroke by 28% (95% CI 17–38%) and the rate of major vascular events by 26% (95% CI 16–34%). Importantly, benefits of treatment were consistent across key patient subgroups, including those with and without hypertension, patients who were Asian and non-Asian, and for both ischaemic and haemorrhagic strokes subtypes.

Current evidence is now strong for clinicians to consider blood pressure-lowering therapy as pivotal in the prevention of stroke, especially in patients with a known history of cerebrovascular disease (and vascular disease, in general), irrespective of blood pressure levels, as soon as patients are clinically stable after an acute stroke or other vascular event. Additional age-specific analyses of the PROGRESS data, together with those from other completed trials, will provide more reliable information about the size of the benefits of blood pressure-lowering therapy, specifically for different age groups, and particularly in the oldest old (those aged >80 years). In the meantime though, an ACE inhibitor plus diuretic treatment regimen that maximises the degree of blood pressure reduction has a good safety profile and is an effective treatment that should be considered in all patients with stroke, including the elderly.

Keywords

Blood Pressure Reduction Blood Pressure Level Perindopril Calcium Channel Antagonist Indapamide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Professor Anderson is a member of the PROGRESS Management Committee and Dr Ratnasabapathy was a Research Fellow associated with the PROGRESS study. Dr Lawes is supported by a Research Training Fellowship of the Health Research Council of New Zealand and is associated with the Asia Pacific Cohort Studies Collaboration. No external funds were used in the preparation of this manuscript.

References

  1. 1.
    Murray CJL, Lopez AD. Global health statistics. Geneva: World Health Organization, 1996Google Scholar
  2. 2.
    World Health Organization. The World Health Report 2002. Reducing risks, promoting healthy life. Geneva: World Health Organization, 2002Google Scholar
  3. 3.
    Bonita R. Epidemiology of stroke. Lancet 1992; 339(8789): 342–4PubMedCrossRefGoogle Scholar
  4. 4.
    Whelton PK. Epidemiology of hypertension. Lancet 1994; 344(8915): 101–6PubMedCrossRefGoogle Scholar
  5. 5.
    Franklin SS, Gustin IV W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure: The Framingham Heart Study. Circulation 1997; 96(1): 308–15PubMedCrossRefGoogle Scholar
  6. 6.
    Burt VL, Culter JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26(1): 60–9PubMedCrossRefGoogle Scholar
  7. 7.
    MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease: part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–74PubMedCrossRefGoogle Scholar
  8. 8.
    Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 336: 827–38CrossRefGoogle Scholar
  9. 9.
    Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033–41CrossRefGoogle Scholar
  10. 10.
    Kilander L Boberg M, Lithell H. How do we treat, or not treat, high blood pressure in the oldest old? Blood Press 1997; 6: 372–6PubMedCrossRefGoogle Scholar
  11. 11.
    Sowers JR, Lester M. Hypertension, hormones, and aging. J Lab Clin Med 2000; 135(5): 379–86PubMedCrossRefGoogle Scholar
  12. 12.
    Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke; 13,000 strokes in 45,000 people in 45 prospective cohorts. Lancet 1995; 346: 1647–53CrossRefGoogle Scholar
  13. 13.
    Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol and stroke in Eastern Asia. Lancet 1998; 352(9143): 1801–7CrossRefGoogle Scholar
  14. 14.
    Asia Pacific Cohort Studies Collaboration. Determinants of cardiovascular disease in the Asia Pacific region: protocol for a collaborative overview of cohort studies. CVD Prevention 1999; 2: 281–9Google Scholar
  15. 15.
    Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13CrossRefGoogle Scholar
  16. 16.
    Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003. In PressGoogle Scholar
  17. 17.
    Anonymous. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265(24): 3255–64Google Scholar
  18. 18.
    Dahlof B, Lindeholm LH, Hansson L, et al. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991; 304: 1281–4CrossRefGoogle Scholar
  19. 19.
    Peart S BP, Broughton PB, Dollery C, et al. Medical Research Council trial of hypertension in older adults: principal results. BMJ 1992; 293: 1281–5Google Scholar
  20. 20.
    Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757–64PubMedCrossRefGoogle Scholar
  21. 21.
    Hansson L, Lithell H, Skoog I, et al. Study on cognition and prognosis in the elderly (SCOPE). Blood Press 1999; 8: 177–83PubMedCrossRefGoogle Scholar
  22. 22.
    Dahlöf B, Devereux RB, Kieldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003PubMedCrossRefGoogle Scholar
  23. 23.
    ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack trial (ALLHAT). JAMA 2002; 288: 2981–97CrossRefGoogle Scholar
  24. 24.
    MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of the evidence in 1994. J Vasc Med Biol 1993; 4(5–6): 265–71Google Scholar
  25. 25.
    MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993; 15(6): 967–78PubMedCrossRefGoogle Scholar
  26. 26.
    Insua JT, Sacks HS, Lau TS, et al. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994; 121(5): 355–62PubMedGoogle Scholar
  27. 27.
    Gueyffier F, Boutitie F, Boissel JP, et al. INDANA: a metaanalysis on individual patient data in hypertension: protocol and preliminary results. Therapie 1995; 50(4): 353–62PubMedGoogle Scholar
  28. 28.
    Gueyffier F, Froment A, Gouton M. New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. J Hum Hypertens 1996; 10(1): 1–8PubMedGoogle Scholar
  29. 29.
    Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279(23): 1903–7PubMedCrossRefGoogle Scholar
  30. 30.
    Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: metaanalysis of outcome trials. Lancet 2000; 355(9207): 865–72PubMedCrossRefGoogle Scholar
  31. 31.
    Mulrow C, Lau J, Cornell J, et al. Pharmacotherapy for hypertension in the elderly. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2002Google Scholar
  32. 32.
    Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed) 1986; 293(6555): 1145–51CrossRefGoogle Scholar
  33. 33.
    Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145–53PubMedCrossRefGoogle Scholar
  34. 34.
    Anonymous. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives: National Intervention Cooperative Study in Elderly Hypertensives Study Group. Hypertension 1999; 34(5): 1129–33Google Scholar
  35. 35.
    Casiglia E, Spolaore P, Mazza A, et al. Effect of two different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study in the Elderly (CASTEL). Jpn Heart J 1994; 35(5): 589–600PubMedCrossRefGoogle Scholar
  36. 36.
    Gueyffier F, Bulpitt C, Boissel J, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999; 353: 793–6PubMedCrossRefGoogle Scholar
  37. 37.
    Gueyffier F, Boissel JP, Boutitie F, et al. Effect of antihypertensive treatment in patients having already suffered from stroke: gathering the evidence. The INDANA (Individual Data Analysis of Antihypertensive intervention trials) Project Collaborators. Stroke 1997; 28(12): 2557–62PubMedCrossRefGoogle Scholar
  38. 38.
    Rodgers A, Neal B, MacMahon S. The effects of blood pressure lowering in cerebrovascular disease: an overview of randomized controlled trials. Neurol Rev Int 1997; 12(1): 12–5Google Scholar
  39. 39.
    PAT Collaborating Group. Post-stroke antihypertensive treatment study: a preliminary result. Chin Med J 1995; 108: 710–7Google Scholar
  40. 40.
    Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324: 699–702PubMedCrossRefGoogle Scholar
  41. 41.
    Meredith PA. Is postural hypotension a real problem with antihypertensive medication? Cardiology 2001; 96Suppl. 1: 19–24PubMedCrossRefGoogle Scholar
  42. 42.
    Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979; I(8121): 861–5CrossRefGoogle Scholar
  43. 43.
    Kannel WB, D’Agostino RB, Silbershatz H. Blood pressure and cardiovascular morbidity and mortality rates in the elderly. Am Heart J 1997; 134(4): 758–63PubMedCrossRefGoogle Scholar
  44. 44.
    Cruickshank JM. The J curve lives [letter]. Lancet 1992; 339(8786): 187PubMedCrossRefGoogle Scholar
  45. 45.
    Cruickshank JM. J curve in antihypertensive therapy: does it exist? A personal point of view. Cardiovasc Drugs Ther 1994; 8(5): 757–60PubMedCrossRefGoogle Scholar
  46. 46.
    D’Agostino RB, Belanger AJ, Kannel WB, et al. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. BMJ 1991; 303(6799): 385–9PubMedCrossRefGoogle Scholar
  47. 47.
    Farnett L, Mulrow CD, Linn WD, et al. The J-curve phenomenon and the treatment of hypertension: is there a point beyond which pressure reduction is dangerous? JAMA 1991; 265(4): 489–95PubMedCrossRefGoogle Scholar
  48. 48.
    Rodgers A, MacMahon S, Gamble G, et al. Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group. BMJ 1996; 313(7050): 147PubMedCrossRefGoogle Scholar
  49. 49.
    Alderman MH. Blood pressure J-curve: is it cause or effect? Curr Opin Nephrol Hypertens 1996; 5(3): 209–13PubMedCrossRefGoogle Scholar
  50. 50.
    Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987; I(8533): 581–4CrossRefGoogle Scholar
  51. 51.
    Cruickshank JM. Antihypertensive treatment and the J-curve. Cardiovasc Drugs Ther 2000; 14(4): 373–9PubMedCrossRefGoogle Scholar
  52. 52.
    MacMahon S, Rodgers A, Neal B, et al. Blood pressure lowering for the secondary prevention of myocardial infarction and stroke. Hypertension 1997; 29(2): 537–8PubMedCrossRefGoogle Scholar
  53. 53.
    Sleight P. Lowering of blood pressure and artery stiffness [letter]. Lancet 1997; 349(9048): 362PubMedCrossRefGoogle Scholar
  54. 54.
    Neaton JD, Blackburn H, Jacob D, et al. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial Research Group. Arch Intern Med 1992; 152(25): 814–20Google Scholar
  55. 55.
    McMurray J, McInnes GT. The J-curve hypothesis. Lancet 1992; 339(8792): 561–2PubMedCrossRefGoogle Scholar
  56. 56.
    Pfeffer MA. Angiotensin-converting enzyme inhibition in congestive heart failure: benefit and perspective. Am Heart J 1993; 126 (3 Pt 2): 789–93PubMedCrossRefGoogle Scholar
  57. 57.
    Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354(9192): 1751–6PubMedCrossRefGoogle Scholar
  58. 58.
    Progress Collaborative Group. The lowering of blood-pressure after stroke [letter]. Lancet 2001; 358(9297): 1994–5Google Scholar
  59. 59.
    Horn J, de Haan RJ, Vermeulen M, et al. Very early nimodipine use in stroke (VENUS): a randomized, double-blind, placebo-controlled trial. Stroke 2001; 32(2): 461–5PubMedCrossRefGoogle Scholar
  60. 60.
    Horn J, Limburg M. Calcium antagonists for ischemic stroke: a systematic review. Stroke 2001; 32(2): 570–6PubMedCrossRefGoogle Scholar
  61. 61.
    Neal B, MacMahon S, Chapman N, et al. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists. Lancet 2000; 356(9246): 1955–64PubMedCrossRefGoogle Scholar
  62. 62.
    Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90(4): 2056–69PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2003

Authors and Affiliations

  • Yogini Ratnasabapathy
    • 1
  • Carlene M. M. Lawes
    • 1
  • Craig S. Anderson
    • 1
    Email author
  1. 1.Clinical Trials Research Unit, Department of MedicineThe University of AucklandAucklandNew Zealand

Personalised recommendations